Neurocapitalism’s Experimental Turn: Depression Implants Tested Amidst Unregulated Mental Health Tech Boom
Original framing: “A Brain Implant for Depression Is About to Be Tested in Humans” — Wired
If neuromodulation scales, we risk a *Brave New World* scenario where 'emotional diversity' is commodified—depression becomes a 'defect' to optimize via subscription-based brain hacks. China’s social credit system already experiments with neural monitoring for 'mental health risks,' suggesting how DBS could merge with state surveillance. Conversely, open-source neurofeedback (e.g., *OpenBCI*) could democratize access, but only if decoupled from venture capital’s extractive logics.
The Motif Neurotech trial exemplifies neurocapitalism’s extraction of human suffering into venture-funded 'solutions,' where a $1.
5B market for depression implants is projected by 2030—despite 70% of global mental health needs remaining unmet. This mirrors historical patterns of medicalizing social crises (from lobotomies to SSRIs) while ignoring colonial legacies (e.g., residential schools’ intergenerational trauma) and Indigenous epistemologies that frame depression as a relational, not biological, disorder. The trial’s focus on 'treatment-resistant' patients—a category shaped by racial bias and pharma marketing—reveals how Silicon Valley’s 'disruptive innovation' serves as a Trojan horse for neoliberal health privatization. Yet cross-cultural models (Yoruba spiritual healing, Tibetan meditation, Māori *whakapapa* frameworks) and trickster critiques (Hermes’ duality, Coyote’s subversion) expose the absurdity of pathologizing human diversity while profiting from its 'correction.' True systemic change demands decolonizing research agendas, redirecting neurotech profits to community sovereignty, and treating mental health as a right—not a hardware upgrade.